Retatrutide includes GIP receptor activation, which makes it mechanistically closer to tirzepatide in one way, while also adding glucagon receptor activity
From an evidence-based standpoint, the answer remains no
In clinical trials examining GLP-1 RA in combination with a sulphonylurea (with or without metformin) or insulin, the incidence of hypoglycemia was low overall, but increased when compared with placebo [114]
Retatrutide and Acid Reflux: Side Effects, Management and UK Guidance Retatrutide and acid reflux is an important consideration for anyone following the development of this investigational triple receptor agonist
Clin Drug Investig 2008;28(8):495-500
95% CI [0.741.22]).41 BP reduction may account for the prevention of haemorrhagic stroke.42 However, elevated haematocrit was also observed in the EMPA-REG OUTCOME trial, which might predispose to ischaemic strokes.11,42,43 Although haemoconcentration improves cardiovascular outcomes, the higher blood viscosity may trigger thrombus formation.27,4244 Although weight loss should protect against ischaemic stroke, compensatory changes may limit weight loss in the long term.33 Although a harmful effect on stroke has not been confirmed, the protective effect on haemorrhagic stroke may mask the effect on ischaemia if both types of stroke are included as a composite endpoint.1618 Population-wide observational studies may help to evaluate the long-term risk of ischaemic strokes during SGLT2 inhibitor therapy